CLAD Phenotype Specific Risk Factors and Mechanisms

Completed

Conditions studied: Lung Transplant, Post Lung Transplantation

In brief

While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejection of the lung by the immune system and is the leading cause of death after lung transplantation. The purpose of this study is to help doctors determine: * why some people get CLAD and others do not * how patients who get CLAD do after CLAD is diagnosed * how CLAD may affect quality of life

Key facts

Study ID

NCT02631720

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

884

Starts

2015-12-22

Expected to finish

2019-11-30

Last updated by the study team

2019-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals who meet all of the following criteria are eligible for enrollment as study participants:
• Subject must be able to understand and provide written informed consent and
• Must be ≥18 years of age at the time of written informed consent.
• Anticipated listing for lung transplantation OR within 45 days of having received a single or bilateral cadaveric donor lung transplant.
• Enrollment must occur prior to the start of bronchoscopies eligible for research bronchoalveolar lavage (BAL) sampling.
• Undergoing first lung transplant operation.
• Transplant surgery to be performed or performed at enrolling center.
• Note: Concurrent participation in immune monitoring studies or interventional device trials are permitted.

You may not qualify if…

• Individuals who meet any of the following criteria are not eligible for enrollment as study participants:
• Multi-organ recipient.
• Prior recipients of any solid organ transplant, including prior lung transplant.
• Prior or concurrent recipient of bone marrow transplant.
• HIV infection.
• Any condition which the investigators feel would make it unlikely for the recipient to complete follow up procedures or complete the study.
• Participation in an investigational drug trial at the time of enrollment visit.

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Duke University — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Toronto — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.